Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial
- Authors
- Park, Hye Jung; Kim, Sae-Hoon; Shin, Yoo Seob; Park, Chul Hwan; Cho, Eun-Suk; Choi, Seung Joon; Park, So Hyun; Jung, Joo Hyun; Kang, Il Gyu; Lee, Myoung Seok; Kim, Dae Woo; Lee, Sang Min; Yang, Min-Suk; Lee, Sang Pyo
- Issue Date
- 4-Jun-2021
- Publisher
- BMC
- Keywords
- Adverse events; Allergen immunotherapy; Allergic rhinitis; Intralymphatic injection; Treatment efficacy
- Citation
- Respiratory Research, v.22, no.1
- Journal Title
- Respiratory Research
- Volume
- 22
- Number
- 1
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81521
- DOI
- 10.1186/s12931-021-01766-0
- ISSN
- 1465-9921
- Abstract
- Background: Most previous studies used aluminum hydroxide-absorbed allergen extracts in evaluating the potential therapeutic roles of intralymphatic allergen-specific immunotherapy (ILAIT). In this study, we evaluated the therapeutic efficacy and safety of ILAIT with L-tyrosine-adsorbed allergen extracts of Dermatophagoides farinae, D. pteronyssinus, cat, dog, or mixtures thereof, in patients with allergic rhinitis induced by these allergens. Methods: In this randomized, double-blind, placebo-controlled trial, study subjects received three intralymphatic injections of L-tyrosine-adsorbed allergen extracts (active group) or saline (placebo group) at 4-week intervals. Results: Although ILAIT reduced daily medication use and skin reactivity to HDM and cat allergens at 4 months after treatment, overall symptom score on a visual analog scale (VAS), sinonasal outcome test-20 (SNOT-20), rhinoconjunctivitis quality of life questionnaire (RQLQ), daily symptom score (dSS), daily medication score (dMS), daily symptom medication score (dSMS), nasal reactivity to HDM allergen, and basophil activity to HDM, cat, and dog allergens at 4 months and 1 year after treatment were similar between the treatment and control groups. Intralymphatic injection was more painful than a venous puncture, and pain at the injection site was the most frequent local adverse event (12.8%); dyspnea and wheezing were the most common systemic adverse events (5.3%). Conclusions: ILAIT with L-tyrosine-adsorbed allergen extracts does not exhibit profound therapeutic efficacy in allergic rhinitis and can provoke moderate-to-severe systemic reactions and cause pain at the injection site. Trial registration: clinicaltrials.gov: NCT02665754; date of registration: 28 January 2016. © 2021, The Author(s).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81521)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.